INFLUENCE OF COMBINED CARRIAGE OF LIPID TRANSPORTING SYSTEM GENES POLYMORPHISMS ON THE GRADE OF CORONARY ATHEROSCLEROSIS IN UNSTABLE ANGINA PATIENTS

Aim. To study the specifics of lipid metabolism and involvement of coronary flow according to combination carriage of “ε4”-allele ε2ε3ε4 polymorphism of gene apolipoproteine Е (Apo Е) and “S2”-allele SstI polymorphism of gene apolipoproteine СIII (Apo СIII) in unstable angina patients.Material and methods. Totally, 141 patients assessed, with unstable angina and angiographically proven coronary atherosclerosis. Comparison group — 50 healthy persons. Genotyping of ε2/ε3/ε4 polymorphism gene Apo Е and SstI polymorphism gene Apo СIII was done by PCR.Results. 37 were selected to one group of patients with the carriage of “harm” alleles: “ε4” and “S2” — (I group), versus the others (II group) — 104 patients. In comparison of lipid profiles, I group showed significantly higher levels of total cholesterol (238,0±54,3 mg/dL) and low density cholesterol (LDL) (154,7±51,5 mg/dL) (Р<0,05), than levels of TC (220,6±39,8) and LDL (138,8±37,6) in II group. Also, in I group patients there was lower HDL cholesterol (34,1±6,3, P<0,05), comparing to II group (36,8±6,8). Level of apolipoproteide В (Apo В) was slightly higher (115,0±24,9 mg/dL), and level of apolipoproteide А-I (Apo А-I) — lower (133,8±21,3) in group I, that led to significantly higher relation of Apo-B/Apo-AI — 0,9±0,3 (P<0,05), comparing to group II (107,0±25,7, 139,1±22,2 and 0,8±0,2), respectively.Conclusion. Carriage of alleles “S2” SstI polymorphism gene apo CIII and “ε4” ε2ε3ε4 polymorphism gene Apo Е is predetermining factor for development of coronary atherosclerosis and atherogenic dyslipidemia among uzbeks. According to coronary arteriography, in the I group patients had more commonly three — and multivessel disease (Р<0,05)

Clinical Status of Patients with Coronary Artery Disease Post COVID-19

The main goal of our study was to identify the activity of cardiac dysfunction based on the analysis of the main cardiological methods of research, such as ECG, echocardiography, 24-hour ECG monitoring in conjunction with laboratory parameters in patients with coronary artery disease (CAD) who underwent mild and moderate COVID-19, without signs of residual effects of lung tissue damage (fibrotization). 52 patients with coronary artery disease were examined, which were divided into 2 groups depending on the past infection in history: 1 group without COVID-19 in history (n=26) (based on history and results of SARS-CoV-2 antibody titer), 2 a group with a history of COVID-19 (n=26), confirmed by relevant documents (tests), but without oxygen therapy and steroids, in order to avoid the influence of a serious illness and drug exposure. Conclusions: dynamic monitoring of hemostasis parameters after the hospital stage in patients with CAD should be carried out in order to prevent adverse cardiovascular outcomes, even with a history of moderate and mild coronavirus infection. One of the aspects of therapeutic rehabilitation in the post-COVID period in patients with IHD is the use of vitamin D preparations